8-K: Myriad Genetics Appoints Ben Wheeler as New CFO

Myriad Genetics, Inc. announced the departure of Scott J. Leffler as Chief Financial Officer and the appointment of Ben R. Wheeler to the role, effective August 16, 2025.

Summary

• Scott J. Leffler no longer serves as Chief Financial Officer of Myriad Genetics, Inc., effective August 15, 2025.
• Mr. Leffler is expected to remain as a non-executive employee for an interim period to assist in the transition of his responsibilities.
• Ben R. Wheeler has been appointed as the new Chief Financial Officer and principal financial officer, effective August 16, 2025.
• Mr. Wheeler, 42, has served in various roles of increasing responsibility at the company for thirteen years, most recently as Senior Vice President, Chief Financial Officer, Operations since June 2022.
• His annual base salary as CFO will be $490,000.
• Mr. Wheeler is eligible to receive an annual target cash bonus equal to 75% of his annual base salary.
• He will also participate in the company's annual long-term incentive compensation program and standard executive benefit plans.
• Mr. Wheeler received an initial one-time grant of 120,000 restricted stock units, split equally between time-based and performance-based vesting.
• The company reaffirmed its financial guidance for the full-year 2025, as announced during its second quarter 2025 earnings call on August 5, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a smooth internal transition of the CFO role, with the company reaffirming its financial guidance, suggesting stability and continuity. The new CFO has extensive internal experience, which is a positive sign.

Positives

• The appointment of Ben R. Wheeler, an internal candidate with 13 years of experience at the company, ensures continuity and deep institutional knowledge in the CFO role.
• Mr. Wheeler's extensive background in various finance leadership positions within Myriad Genetics suggests a smooth transition and strong understanding of the company's operations.
• Myriad Genetics reaffirmed its full-year 2025 financial guidance, indicating stability and confidence in its financial outlook despite the executive change.

Negatives

• The filing does not provide a specific reason for the departure of the previous Chief Financial Officer, Scott J. Leffler.

Risks

• Forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated.
• Such factors include those risks described in the company's Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Future Outlook

Myriad Genetics reaffirmed its financial guidance for the full-year 2025. The company anticipates that Ben Wheeler's extensive knowledge, financial expertise, and leadership will be instrumental in executing its profitable growth strategy going forward.

Management Comments

• "We want to thank Scott for his contributions to Myriad. We are happy to have Ben as our next CFO. His extensive knowledge of our business, strong financial expertise, and proven leadership will be instrumental in enabling the execution of our profitable growth strategy going forward." Sam Raha, President and CEO of Myriad Genetics.
• "I'm excited for this opportunity to lead the finance team and play a pivotal role in advancing Myriad's mission and long-term growth strategy. I look forward to partnering with Sam and the rest of the executive team to positively impact an increasing number of patient lives and to generate lasting value for our shareholders." Ben R. Wheeler.

Industry Context

Executive leadership changes, particularly in the Chief Financial Officer role, are a common occurrence in publicly traded companies. An internal promotion, as seen with Ben Wheeler, often signals continuity and a deep understanding of the company's operations and strategic direction, which can be viewed positively by the market compared to an external hire who would require a longer onboarding period. This change occurs within the molecular diagnostic testing and precision medicine industry, where robust financial stewardship is crucial for managing research and development investments, navigating regulatory complexities, and executing market expansion strategies.

Comparison to Industry Standards

• The internal promotion of a long-tenured finance executive like Ben Wheeler (13 years with the company) is a common and often preferred practice in the biotechnology and diagnostics sector, as it ensures continuity and leverages existing institutional knowledge. This approach is frequently adopted by companies like Exact Sciences or Guardant Health for key leadership roles to maintain strategic alignment.
• The compensation package for the new CFO, including a base salary of $490,000 and a 75% target bonus, is generally competitive for a CFO role at a company of Myriad Genetics' size and market capitalization within the molecular diagnostics industry. This aligns with typical executive compensation structures that blend fixed salary with performance-based incentives to attract and retain top talent.
• Reaffirming full-year financial guidance immediately after a CFO transition is a strong signal of confidence and stability, a practice often adopted by well-managed companies to mitigate investor uncertainty during leadership changes. This contrasts with companies that might withdraw or revise guidance, which can signal underlying operational or financial issues.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to continuity in leadership and reaffirmed financial guidance, which may reduce uncertainty.
• Employees: Internal promotion can boost morale and demonstrate clear career progression opportunities within the company.
• Customers: No direct immediate impact on customer relations or services is expected.
• Suppliers: No direct immediate impact on supplier relationships is expected.
• Creditors: Reaffirmed guidance and stable leadership may maintain confidence in the company's financial stability.

Next Steps

• The Employment Agreement with Mr. Wheeler will be filed with the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.
• The company will continue to execute its profitable growth strategy under the leadership of the new Chief Financial Officer.

Key Dates

Recommendation

The filing details a routine executive transition with an internal promotion to CFO and a reaffirmation of financial guidance. This suggests stability and continuity rather than a significant change in the company's strategic direction or financial health. While the departure of the previous CFO is noted, the immediate internal replacement and reaffirmed guidance mitigate potential negative sentiment. Therefore, a 'hold' recommendation is appropriate as this event does not present new information that would fundamentally alter the investment thesis, either positively or negatively, to warrant a 'buy' or 'sell' action.

Keywords

Myriad Genetics, MYGN, CFO, Chief Financial Officer, Executive Change, Corporate Governance, Financial Reporting, Molecular Diagnostics, Precision Medicine, SEC Filing, 8-K